BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2014

View Archived Issues

Clinical study evaluates immunological response EMD-640744 in solid tumors

Read More

Shandong Xuanzhu Pharmaceutical Technology patents novel inhibitors for cancer

Read More

Mitsubishi Tanabe Pharma discloses new TRPM8 agonists for chronic pain

Read More

Meda and Valeant terminate joint ventures in Canada, Mexico and Australia

Read More

Santen and Oak Pharmaceuticals sign U.S. tafluprost licensing agreement

Read More

Pharmacokinetic bioequivalence of biosimilar GP-2017 and reference adalimumab

Read More

Lilly and Deciphera Pharmaceuticals present data on LY-3009120

Read More

Aptiom launched in the U.S. for use as adjunctive treatment of partial-onset seizures

Read More

Novel dendrimer-drug conjugates patented by Indian university

Read More

Mersana Therapeutics and Takeda to develop next-generation antibody-drug conjugates

Read More

IGM-55.5 potently binds and kills B cells in NHL patients

Read More

Soligenix receives SBIR grant award supporting phase II trial of SGX-942

Read More

JNJ-61186372 demonstrates activity for the treatment EGFR/c-Met-aberrant malignancies

Read More

Genentech and Array BioPharma reports ERK-1/2 inhibitor, GDC-0994

Read More

Abbott and AbbVie disclose new PDE10A inhibitors

Read More

Roche and Oryzon to develop epigenetics-based medicines

Read More

Pradaxa approved for deep venous thrombosis and pulmonary embolism

Read More

Merck & Co., Ferring and WHO to study room temperature-stable carbetocin for post-partum hemorrhage

Read More

Daiichi Sankyo extends European PREFER in AF registry

Read More

Cancer Genetics launches CALR mutation analysis test

Read More

Arno Therapeutics enrolls first patient in phase I/II onapristone trial in prostate cancer

Read More

Bristol-Myers Squibb submits daclatasvir and asunaprevir NDAs to FDA for HCV

Read More

Sun Pharmaceutical to acquire Ranbaxy Laboratories from Daiichi Sankyo

Read More

RedHill Biopharma to submit European MAA for RHB-102

Read More

Xenetic Biosciences reports phase I data for PulmoXen in cystic fibrosis

Read More

OncoSec Medical to relaunch phase II CTCL trial of ImmunoPulse DNA IL-12

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing